Disulfidptosis belongs to the growing family of programmed cell death modalities, which already includes apoptosis, necroptosis, pyroptosis, ferroptosis and cuproptosis. What sets it apart is its peculiar trigger and its equally peculiar execution mechanism. Rather than being launched by genetic damage, immune signaling or lipid peroxidation, disulfidptosis arises when a cancer cell suffers a catastrophic metabolic and redox imbalance, one that culminates in the irreversible collapse of the actin cytoskeleton, the internal scaffold that gives the cell its shape and motility. In the simplest terms, the cell’s skeleton literally disintegrates under the strain of accumulated disulfide bonds, and the cell dies.

At the heart of the process lies what the authors describe as the SLC7A11-cystine-NADPH-actin axis. SLC7A11, also known as xCT, is a cystine/glutamate antiporter that many cancer cells upregulate to import cystine, the oxidized dimer of cysteine, which they then reduce to cysteine for the synthesis of glutathione and other antioxidant molecules. This import strategy works well for tumor cells as long as they have abundant glucose, because glucose feeds the pentose phosphate pathway, which generates NADPH, the reducing power needed to convert incoming cystine back into cysteine. The transporter, in other words, is a double-edged sword: it equips cancer cells to withstand oxidative stress, but it creates a hidden dependency on a continuous supply of NADPH.

The vulnerability is exposed when glucose runs out. Under glucose starvation, NADPH production collapses, and the cystine that continues to flood into the cell through SLC7A11 can no longer be reduced. Abnormal levels of intracellular cystine and other disulfide molecules accumulate, and aberrant disulfide bonds begin to form between cysteine residues on a broad range of proteins. Previous work by Liu and colleagues, published in Nature Cell Biology in 2023, demonstrated that the actin cytoskeleton is particularly susceptible to this disulfide stress. When excessive disulfide bonding disrupts actin networks, the cytoskeleton collapses, cells detach from their surroundings, shrink and die. This actin-centered death is the defining hallmark of disulfidptosis.

The review also emphasizes why certain cancer cells are unusually susceptible to this death route. Tumors are metabolically rewired cells, and many of them, including those with high SLC7A11 expression, exist in a state the authors call a fragile redox equilibrium, balancing heavy cystine import against tight NADPH budgets. Notably, cells that have evolved resistance to apoptosis or to ferroptosis, the iron-dependent lipid peroxidation death, often show heightened vulnerability to disulfidptosis, suggesting that this pathway could be exploited against tumors that have outmaneuvered conventional therapies. This synthetic-lethal logic, where a second stress is applied to cells already carrying a metabolic liability, underlies much of the enthusiasm surrounding the field.

Regulation of disulfidptosis is a multi-layered affair, spanning metabolic, redox and signaling networks. On the metabolic side, glucose uptake through transporters such as GLUT1 and GLUT3, glycolytic flux, and activity of the pentose phosphate pathway enzymes glucose-6-phosphate dehydrogenase (G6PD) and 6-phosphogluconate dehydrogenase all determine how much NADPH a cell can muster. The review highlights that cancer cells can draw NADPH from alternative sources, including lactate and glutamine metabolism, when glucose is scarce, which complicates therapeutic strategies based purely on glucose deprivation. On the redox side, the glutathione system, comprising glutathione, glutathione peroxidases and glutathione reductase, and the thioredoxin system, comprising thioredoxin, thioredoxin reductase and related proteins such as TRP14, act as buffers against disulfide stress. Inhibiting thioredoxin reductase 1, for example, has been shown to sensitize glucose-starved glioblastoma cells to disulfidptosis, as reported by Tang and colleagues in Cell Death and Differentiation in 2025.

Several key signaling pathways tune this machinery. The Keap1-Nrf2 pathway, the master sensor of oxidative and electrophilic stress, regulates the expression of SLC7A11 and a suite of antioxidant genes, and its frequent activation in tumors, through Keap1 mutations or NRF2 stabilization, can either protect cells from disulfide stress or, paradoxically, load them with more cystine import capacity that becomes lethal when energy fails. The AMPK pathway, activated under energy stress through LKB1 and other sensors, helps cells conserve NADPH and survive glucose starvation; cells with LKB1 mutations, such as a subset of non-small cell lung cancers, are consequently more likely to die by disulfidptosis when deprived of glucose. The tumor suppressor p53 adds another layer of complexity, shaping glucose metabolism and redox gene expression in ways that can either sensitize or protect cells depending on context.

The review also details the cytoskeletal components that serve as executioners of the process. Rac1, a small GTPase that governs actin polymerization, activates the WAVE regulatory complex, which includes NCKAP1 and the Arp2/3-activating machinery that drives branched actin network formation. Disulfide stress-induced aberrant bonding among actin and its interacting proteins cripples these structures, and studies have shown that manipulating Rac1-WAVE signaling alters sensitivity to disulfidptosis. Because many of these same proteins also drive cancer cell migration, invasion and metastasis, the actin cytoskeleton represents a doubly attractive target: disrupting it kills vulnerable tumor cells and simultaneously undermines their ability to spread.

Importantly, the authors caution that the story is not uniformly favorable. Functional polarity reversal of core regulatory molecules, in which a factor that normally promotes disulfidptosis in one context protects against it in another, and the profound heterogeneity of tumors can both blunt therapeutic efficacy. Some tumors with low SLC7A11 expression may be resistant, while others compensate through alternative NADPH-generating routes. This heterogeneity is one of the principal bottlenecks the field must overcome, alongside a shortage of highly specific pharmacological tools to induce or inhibit disulfidptosis selectively.

Despite these challenges, early translational efforts are encouraging. Researchers have developed nanoinducers, including copper-based nanoparticles and FTO-targeting nanodrugs, that promote disulfidptosis while simultaneously remodeling the immunosuppressive tumor microenvironment, thereby boosting immunotherapy. Sonodynamic nanoparticles carrying GLUT1 inhibitors and cystine-containing polymers have been tested in bladder cancer models. Combination strategies pairing disulfidptosis induction with ferroptosis, cuproptosis or pyroptosis, or with agents that inhibit DNA repair and force cell cycle arrest, are being explored to enhance tumor killing. The review argues that the selectivity of disulfidptosis for metabolically vulnerable cancer cells, which spares normal cells that lack the same cystine-import dependence, offers a route toward therapies with a wider therapeutic window than conventional cytotoxic chemotherapy.

Looking forward, the authors call for precise molecular classification systems that identify which tumors carry the disulfidptosis-susceptible phenotype, development of targeted drugs against the SLC7A11-NADPH-actin axis, and exploration of synergistic strategies combining metabolic interventions with immunotherapy. If those goals can be met, disulfidptosis may move from a laboratory curiosity to a genuine clinical option, giving oncologists a way to exploit the very metabolic addictions that cancer cells rely on for survival. For now, the field stands at an inflection point, with the fundamental biology largely mapped and the first-generation tools beginning to emerge, and the coming years will determine whether the actin cytoskeleton, that ancient structural scaffold of the cell, becomes the next great target in cancer medicine.

Traditionally known for their often severe treatment side effects and significant impact on quality of life, HNSCCs rank as the seventh most frequently diagnosed cancer globally, with almost 890,000 new cases reported annually. For patients diagnosed with these malignancies, the need for effective therapies that not only shrink tumors but also preserve functionality—especially essential organs like the tongue and voice box—remains paramount. The research, published on March 13, 2025, in the esteemed journal Cancer Cell, illuminates an exciting path forward in this complex therapeutic landscape.

At the core of the study is the observation that patients receiving a combination of immunotherapy drugs exhibited substantially higher response rates compared to those treated with a single drug. Specifically, the trial categorized 42 patients into three distinct arms: nivolumab alone, nivolumab in conjunction with ipilimumab, and nivolumab paired with relatlimab. Each combination demonstrated remarkably high efficacy, with some patients experiencing over a 50% reduction in tumor size within just one month. This significant finding indicates a robust response that is critical not only in terms of immediate tumor reduction but also points toward improved survival outcomes.

The significance of these findings is amplified by an analysis of immune cell response within patients’ tumors. By examining the types of T lymphocytes activated during treatment, researchers have identified specific biological markers that could allow tailored therapeutic approaches. This individualized treatment paradigm is crucial, as it presents an opportunity to harness the body’s immune system more effectively against cancer. The notion that the immune status at diagnosis can guide treatment decisions adds a layer of sophistication to cancer therapy that has not been previously articulated.

Encouragingly, the study highlights a pivotal role for the Lymphocyte Activation Gene-3 (LAG-3) protein as a potential biomarker, effectively distinguishing patients who might respond favorably to different immunotherapy combinations. This diagnostic insight could lead to more personalized and effective treatment regimens, changing the landscape of cancer therapy where patients often receive one-size-fits-all approaches.

Dr. Ferris, who initiated this innovative research during his tenure at UPMC Hillman Cancer Center, elaborated on the disappointing historical performance of single-drug immunotherapies. He noted that while such therapies demonstrated some benefit, they were markedly limited in their impact on the broader patient population. The trial’s results, which effectively doubled or tripled response rates compared to single-agent therapies, could potentially redefine treatment standards for HNSCCs.

As the research team continues to explore the intricate dynamics of immune activation and tumor regression, they have simultaneously expanded the clinical trial to encompass an additional 40 patients. This larger cohort aims to evaluate the efficacy of higher doses of relatlimab as researchers seek to refine treatment approaches further and ultimately extend survival rates.

This research holds not only promise for clinical application but could also shift how we understand the immune interactions at play in cancer. With immunotherapy now firmly entrenched in oncology practice, studies like the one led by Dr. Ferris emphasize the need for ongoing exploration of not just how these treatments work in isolation, but how their mechanisms can be optimized through combination approaches.

As discussions about the future of cancer treatment evolve, ongoing research and clinical trials will play a crucial role in determining how best to utilize immunotherapies for maximum patient benefit. Understanding immune cell dynamics and the potential for biological markers to refine treatment strategies represents a significant advancement in personalized medicine.

In a broader context, this line of inquiry underscores a monumental shift in cancer research, away from purely tumor-centric approaches toward an integrative view of patient health that considers the vital relationship between immune function and treatment efficacy. As the scientific community continues to push these boundaries, the possibility of not only improved treatments but also enhanced patient experiences becomes increasingly tangible.

For HNSCC patients, the implications of Dr. Ferris’s research could herald a new era of treatment where better responses and quality-of-life preservation are attainable. Armed with the findings of this trial, clinicians may soon be better equipped to tailor therapies, interfacing more effectively with the body’s natural defenses against cancer.

Overall, the trial’s findings not only exemplify the potential of immunotherapy in clinical practice but also elucidate a pathway for further research that could extend beyond head and neck cancers into other malignancies where similar strategies may yield beneficial outcomes in treatment.

Subject of Research: People
Article Title: Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies
News Publication Date: 13-Mar-2025
Web References:
References:
Image Credits: Credit: UPMC

Keywords: Head and neck cancer, Cancer immunotherapy, Drug combinations, Cancer medication

Dr. Kalyan M. Shekhda, along with his co-authors, dives into the groundbreaking potential of alpha particle therapy as a viable alternative for treating neuroendocrine tumors. The review digs deep into the advanced science of TAT, elucidating its mechanisms of action, practical applications, and the potential it holds for patients, especially those resistant to other forms of treatment. With the increasing incidence of NETs, stemming from earlier diagnostics and rising awareness, the need for effective treatment options has never been more critical.

The evolution of our understanding of NETs began over 150 years ago, revealing a persistent challenge for oncologists and researchers alike. Traditionally, the only curative measure has been the complete surgical removal of tumors; however, the rising incidence of NETs has fueled a demand for alternative therapies. One of the mainstays in NET treatment has been peptide receptor radionuclide therapy (PRRT), which combines radioactive particles with targeting molecules that focus on cancer cells. While beta-particle emitters like Lutathera have been instrumental in this arena, their efficacy has diminished due to relapse rates within a few years, underscoring the necessity for new solutions.

This urgent quest for innovation has led researchers to the serious advantages presented by alpha particles. These particles are particularly powerful, emitting high-energy bursts that can cause significant damage to tumor DNA without harming the surrounding healthy tissue. This property makes them uniquely effective for treating tumors that exist in hypoxic environments, where conventional therapies may struggle to penetrate due to oxygen scarcity. The ability of alpha particles to deliver such a powerful blow directly to tumor cells positions them as a potential game-changer in the treatment of resistant NETs.

The fascinating physics behind TAT reveals why it holds so much promise. Alpha particles are characterized by a high linear energy transfer (LET), a property that enables them to create multiple double-strand breaks in DNA. This lethal capacity far exceeds that of beta emitters, which typically result only in single-strand breaks that may allow cancer cells to recover. As Dr. Shekhda has articulated, "Alpha particles are like surgical strikes—short-range, high-impact, and devastating to tumors, even in low-oxygen environments where other therapies falter." This unique potency is leading researchers to ponder the question: Could targeted alpha therapy redefine treatment for patients with therapy-resistant NETs?

Co-author Dr. Shaunak Navalkissoor elaborates on the broader implications of TAT in clinical settings. He notes the technique’s suitability as a precision tool for patients who have already exhausted conventional therapeutic options. Clinical experiences suggest that alpha particles may aid in overcoming the resistance mechanisms that frequently characterize traditional treatments. By harnessing the localized and high-impact nature of alpha radiation, oncologists can provide substantial treatment directly to tumor cells while sparing healthy tissues, which is a crucial consideration in cancer therapy.

Initial preclinical investigations involving alpha-emitting isotopes such as Ac-225-DOTATATE and Pb-212-DOTAMTATE have demonstrated significant promise in delaying tumor growth while causing minimal toxicity to critical human organs. Although clinical studies are still in their infancy, preliminary findings are encouraging. For instance, a phase I trial focusing on Pb-212-DOTAMTATE revealed an 80% disease control rate among patients naïve to PRRT, earning it a designation of Breakthrough Therapy from the FDA. Additionally, Ac-225-DOTATATE is boasting nearly a 90% disease control rate in certain cohorts suffering from progressive NETs. However, questions remain regarding the long-term efficacy and potential adverse effects of TAT—a topic for upcoming clinical trials that the research community eagerly anticipates.

Reflecting on the journey of oncology, this article also pays homage to Dr. Seymour Reichlin, a pivotal figure in the field of neuroendocrinology, whose 100th birthday is marked with this special review. Dr. Reichlin’s enduring legacy encompasses the foundational work he has done related to neuroendocrine biology, and this review touches upon his contributions while framing the ongoing conversations around the potential of TAT to usher in new advances in treatment strategies for endocrine cancers.

Despite the vast potential of TAT, significant challenges remain. The rapid decay of alpha-emitters, such as Bi-213, presents major hurdles for production and transport, which complicates their availability and application in clinical scenarios. Furthermore, logistical challenges such as stringent regulatory requirements, high costs, and the intricacies involved in dosimetry for radiation are all barriers yet to be overcome. However, innovation is on the horizon as companies strive to develop new Pb-212 generators, and advancements in microdosimetry techniques could enhance the safety profiles of such treatments.

While the risks associated with TAT, such as potential toxicity, are a concern, the reported incidence of severe side effects is relatively low. A meta-analysis suggests that severe adverse events occur in about 2-3% of cases, although longitudinal data on delayed effects are still lacking. Importantly, the kidneys may prove to be susceptible to damage from the intense energy of alpha particles, prompting inquiries into the use of adjunctive therapies such as chemotherapy or PARP inhibitors to maximize efficacy while minimizing risk.

This moment in the history of cancer research is vital as NETs continue to rise, and the innovative targeted alpha therapy presents a lifeline for patients where existing beta therapies have fallen short, particularly in cases of resistance. With ongoing trials, such as the ACTION-1 study utilizing Ac-225-DOTATATE, set to draw comparisons with standard care, the coming years are pivotal. On the edge of what could be an oncological breakthrough, questions loom regarding how TAT might transition from experimental stages to mainstream application and how it could influence our overall understanding and treatment of multiple cancer types.

In conclusion, this peer-reviewed article not only encapsulates advanced scientific insights but also serves as a tribute to Dr. Reichlin’s lasting influence in the field of neuroendocrinology. It narrates a compelling convergence of historical influence and future possibilities, offering compelling narratives that underscore both the urgency and the transformative potential of targeted alpha therapy for neuroendocrine tumors.

Subject of Research: Neuroendocrine tumors (NETs)
Article Title: Alpha particle therapy for neuroendocrine tumours: A focused review
News Publication Date: 4-Mar-2025
Web References: Journal Link
References: Brain Medicine
Image Credits: Dr. Kalyan M Shekhda

Keywords: Neuroendocrine tumors, targeted alpha therapy, cancer treatment, beta emitters, precision medicine, DNA damage, preclinical trials, alpha particles, oncology, Dr. Seymour Reichlin, breakthrough therapy.